Locally advanced prostate cancer—biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate‐specific antigen recurrence after radiotherapy
Open Access
Abstract
BACKGROUND.: Biochemical results from a prospective Phase II trial of intermittent androgen suppression for recurrent prostate cancer after radiotherapy were analyzed for correlations to the onset of hormone‐refractory disease.METHODS.: Patients with histologically confirmed adenocarcinoma of the prostate and a rising serum prostate‐specific antigen (PSA) level after external beam irradiation of the prostate were treated intermittently with a 36‐week course of cyproterone acetate and leuprolide acetate. Then, patients were stratified according to their serum PSA range at the start of each cycle and were followed with further biochemical testing until disease progression was evident.RESULTS.: The mean PSA reduction was 95.2% irrespective of stratification group. A baseline serum PSA level P = .0002). Recovery of serum testosterone to a level of ≥7.5 nmol/L was observed in 75%, 50%, 40%, and 30% of men in Cycles 1 to 4, respectively, and was sufficient to normalize the level of hemoglobin in each cycle, which dropped by an average of 10.8 g/L during treatment (P < .0001).CONCLUSIONS.: The length of the off‐treatment interval during cyclic androgen withdrawal therapy was related inversely to baseline and nadir levels of serum PSA. Nadir PSA was a powerful predictor of early progression to androgen independence. Cancer 2007 © 2007 American Cancer Society.Keywords
This publication has 11 references indexed in Scilit:
- Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancerCancer, 2006
- Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?Journal of Clinical Oncology, 2005
- A PROSPECTIVE ANALYSIS OF THE TIME TO NORMALIZATION OF SERUM ANDROGENS FOLLOWING 6 MONTHS OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS ON A RANDOMIZED PHASE III CLINICAL TRIAL USING LIMITED HORMONAL THERAPYJournal of Urology, 2005
- Intermittent Androgen Deprivation Therapy for Prostate CancerThe Oncologist, 2004
- Intermittent Maximal Androgen Blockade in Patients with Metastatic Prostate Cancer: An EORTC Feasibility StudyEuropean Urology, 2003
- A 10-Year Clinical Experience with Intermittent Hormonal Therapy for Prostate CancerEuropean Urology, 2003
- A PROSPECTIVE ANALYSIS OF TIME TO NORMALIZATION OF SERUM TESTOSTERONE AFTER WITHDRAWAL OF ANDROGEN DEPRIVATION THERAPYJournal of Urology, 2000
- Prostate cancer: molecular biology of early progression to androgen independence.Endocrine-Related Cancer, 1999
- Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigenCancer, 1993
- Circadian Variation in Testosterone, Sex Hormone‐Binding Globulin, and Calculated Non‐Sex Hormone‐Binding Globulin Bound Testosterone in Healthy Young and Elderly MenJournal of Andrology, 1989